

Russell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1	nc	(nc-nc)
Female	6	6.6	90.4	(33-196.7)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	5	1.7	298.3	(96.1-696.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	4	7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	0.6	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rutland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	6	149.1	(68-283)	Male	3	4.4	nc	(nc-nc)
Female	1	2	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	25	26.2	95.3	(61.7-140.7)	Female	3	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	7.5	93.4	(37.4-192.4)	Female	1	2.3	nc	(nc-nc)
Female	6	6.5	92.5	(33.8-201.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.1	nc	(nc-nc)
Male	2	1.8	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	25.3	95	(60.9-141.4)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	2	3.8	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.9	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	5.8	85.8	(27.6-200.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.6	nc	(nc-nc)	Female	7	5.8	119.9	(48-247)
Female	0	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	81	89.7	90.3	(71.7-112.3)
Male	1	2.2	nc	(nc-nc)	Female	70	84.1	83.3	(64.9-105.2)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	11.2	88.9	(42.6-163.5)					
Female	8	10.5	75.8	(32.7-149.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	41	41.1	99.7	(71.5-135.2)	Male	23	27.1	84.8	(53.8-127.3)
Female	19	16.4	115.8	(69.7-180.8)	Female	23	24.2	95	(60.2-142.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.2	122.3	(58.6-225)	Male	2	7.4	nc	(nc-nc)
Female	4	7.4	nc	(nc-nc)	Female	6	6.6	90.7	(33.1-197.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	32	23.9	133.9	(91.6-189)
Female	197	173.5	113.5	(98.2-130.5)	Female	22	21.6	101.9	(63.9-154.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	6.4	77.8	(25.1-181.6)	Male	15	17.8	84.3	(47.2-139.1)
<u>Colon / Rectum</u>					Female	9	8.6	104.9	(47.9-199.2)
Male	53	46.7	113.5	(85-148.5)	<u>Ovary</u>				
Female	46	52.1	88.4	(64.7-117.9)	Female	13	15.9	81.7	(43.5-139.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	11	144.9	(82.7-235.3)	Male	14	13.5	103.4	(56.5-173.4)
Female	4	3.3	nc	(nc-nc)	Female	20	15.9	126	(76.9-194.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.7	nc	(nc-nc)	Male	164	153.2	107.1	(91.3-124.8)
Female	7	3.4	207.8	(83.2-428.2)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	9.8	163.7	(93.5-265.9)
Male	31	22	140.6	(95.5-199.6)	Female	6	6.4	94	(34.3-204.6)
Female	14	13.9	100.4	(54.8-168.5)	<u>Testis</u>				
<u>Larynx</u>					Male	5	6.4	78.5	(25.3-183.1)
Male	7	6	115.9	(46.4-238.8)	<u>Thyroid</u>				
Female	4	2	nc	(nc-nc)	Male	13	10.1	129.1	(68.7-220.7)
<u>Leukemia</u>					Female	34	34.3	99.3	(68.7-138.7)
Male	22	16.2	135.7	(85-205.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	13.1	91.6	(47.3-160)	Female	41	39.7	103.2	(74-140)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	12.9	108.9	(59.5-182.7)	Male	607	555.6	109.2	(100.7-118.3)
Female	4	4.8	nc	(nc-nc)	Female	613	601.5	101.9	(94-110.3)
<u>Lung and Bronchus</u>									
Male	72	74.8	96.2	(75.3-121.2)					
Female	83	84.2	98.6	(78.5-122.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Salisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	9.2	162.8	(91-268.5)	Male	11	6.3	174.4	(86.9-312)
Female	3	3.2	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.9	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	5.5	nc	(nc-nc)
Female	49	37.4	131.1	(97-173.4)	Female	10	4.3	231.1	(110.7-425.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	5	4.4	112.9	(36.4-263.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	15	10.8	139.2	(77.9-229.7)	Female	4	3.3	nc	(nc-nc)
Female	14	10	140.2	(76.6-235.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.1	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	Female	3	3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	31	38.4	80.8	(54.9-114.7)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.2	nc	(nc-nc)
Male	7	5.4	130.7	(52.4-269.3)	<u>Testis</u>				
Female	3	2.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.6	nc	(nc-nc)	Female	12	8.8	135.7	(70.1-237.1)
Female	3	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	133	131.2	101.4	(84.9-120.1)
Male	3	3.2	nc	(nc-nc)	Female	155	123.7	125.3	(106.3-146.6)
Female	1	1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	17.3	92.3	(52.7-149.9)					
Female	29	17.4	167	(111.9-239.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandisfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	4.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.8	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	6.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.8	nc	(nc-nc)	Female	0	1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	0.5	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
					Male	10	21.6	46.3	(22.1-85.1)
					Female	8	13.5	59.3	(25.5-116.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sandwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	25	24.2	103.3	(66.9-152.5)	Male	26	15.7	165.3	(108-242.3)
Female	8	8.6	92.8	(40-182.9)	Female	21	12.3	171	(105.8-261.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.6	151.5	(60.7-312.1)	Male	3	4.4	nc	(nc-nc)
Female	6	3.8	157.3	(57.5-342.5)	Female	1	3.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	18	13.8	130.2	(77.2-205.9)
Female	105	93.7	112	(91.6-135.6)	Female	15	11.3	132.7	(74.2-218.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.3	nc	(nc-nc)	Male	13	10.6	123	(65.4-210.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	27.4	84	(53.2-126)	Female	7	8.4	83.1	(33.3-171.3)
Female	28	27.2	103.1	(68.5-149)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	8	125.3	(60-230.4)
Male	7	6.6	106.4	(42.6-219.2)	Female	8	8.3	96.5	(41.6-190.2)
Female	1	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	119	92.1	129.2	(107-154.6)
Male	3	1.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.5	nc	(nc-nc)	Male	6	5.7	104.5	(38.2-227.4)
<u>Kidney & Renal Pelvis</u>					Female	5	3.3	150.6	(48.5-351.5)
Male	10	13	76.8	(36.8-141.3)	<u>Testis</u>				
Female	7	7.4	94.3	(37.8-194.3)	Male	3	2.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	3.6	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	11	17	64.8	(32.3-116)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	14	9.3	150.7	(82.3-252.9)	Female	22	21.5	102.2	(64-154.8)
Female	5	6.7	74.3	(23.9-173.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	359	326.6	109.9	(98.8-121.9)
Male	5	7.7	65	(21-151.7)	Female	318	317.5	100.2	(89.5-111.8)
Female	1	2.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	44.5	56.2	(36.4-83)					
Female	39	44.9	86.8	(61.7-118.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Saugus

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	35.7	112	(80-152.5)	Male	11	22.5	48.9	(24.4-87.4)
Female	15	12.9	116	(64.9-191.4)	Female	11	17.5	62.7	(31.3-112.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	6.3	nc	(nc-nc)	Male	5	6.4	78.7	(25.4-183.6)
Female	12	5.4	224.1	(115.7-391.6)	Female	2	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	21	19.7	106.5	(65.9-162.8)
Female	139	132.7	104.7	(88-123.6)	Female	12	16.6	72.3	(37.3-126.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.5	nc	(nc-nc)	Male	20	14.7	135.9	(83-209.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	44	39.5	111.5	(81-149.7)	Female	7	12.1	57.8	(23.2-119.1)
Female	39	40.2	97.1	(69-132.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	11.7	77.1	(35.2-146.4)
Male	10	9.5	105.4	(50.5-193.9)	Female	14	12.5	112.2	(61.3-188.3)
Female	4	2.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	104	131.7	79	(64.5-95.7)
Male	4	2.5	nc	(nc-nc)	<u>Stomach</u>				
Female	2	2	nc	(nc-nc)	Male	11	8.3	132	(65.8-236.2)
<u>Kidney & Renal Pelvis</u>					Female	3	4.9	nc	(nc-nc)
Male	26	18.3	142.4	(93-208.6)	<u>Testis</u>				
Female	10	10.8	92.6	(44.3-170.3)	Male	11	3.7	294.7	(146.9-527.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	5.2	135.3	(54.2-278.9)	Male	8	7.7	104	(44.8-204.9)
Female	3	1.6	nc	(nc-nc)	Female	18	23.1	77.8	(46.1-123)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	13.3	128.2	(74.6-205.3)	Female	25	31	80.7	(52.2-119.2)
Female	6	9.7	61.8	(22.6-134.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	468	469.1	99.8	(90.9-109.2)
Male	11	10.8	101.6	(50.6-181.7)	Female	450	459.6	97.9	(89.1-107.4)
Female	1	3.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	71	65.1	109.1	(85.2-137.6)					
Female	78	67.4	115.8	(91.5-144.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Savoy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	1	0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.5	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Male</u>				
Male	0	0.1	nc	(nc-nc)	7	12.7	55.3	(22.1-113.8)	
Female	0	0	nc	(nc-nc)	<u>Female</u>				
<u>Leukemia</u>					<u>5</u>				
Male	0	0.3	nc	(nc-nc)	9.6	52.1	(16.8-121.6)		
Female	0	0.2	nc	(nc-nc)					
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	0.3	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.7	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Scituate

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	23.1	133.9	(91-190.1)	Male	42	14.9	282	(203.2-381.1)
Female	10	8.2	121.9	(58.4-224.2)	Female	33	11.4	289.3	(199.1-406.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.3	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	7	3.3	209.8	(84.1-432.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	17	13	130.8	(76.2-209.5)
Female	109	88.4	123.3	(101.2-148.8)	Female	11	10.7	102.9	(51.3-184.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3	nc	(nc-nc)	Male	18	10.1	179	(106-282.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	26	84.5	(52.9-127.9)	Female	6	8	75.4	(27.5-164.2)
Female	20	25.7	77.8	(47.5-120.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	7.7	nc	(nc-nc)
Male	6	6.4	94.5	(34.5-205.6)	Female	9	7.9	114.1	(52.1-216.6)
Female	0	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	74	89.8	82.4	(64.7-103.4)
Male	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.3	nc	(nc-nc)	Male	6	5.5	109.5	(40-238.3)
<u>Kidney & Renal Pelvis</u>					Female	2	3.1	nc	(nc-nc)
Male	5	12.4	40.3	(13-94.2)	<u>Testis</u>				
Female	5	7.1	70.8	(22.8-165.3)	Male	2	2.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.5	nc	(nc-nc)	Male	3	5.2	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	17	15.4	110.7	(64.5-177.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	8.7	114.5	(54.8-210.6)	Female	16	20.5	77.9	(44.5-126.5)
Female	10	6.3	158.6	(75.9-291.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	315	312.6	100.8	(90-112.5)
Male	6	7.3	81.7	(29.8-177.9)	Female	344	299.7	114.8	(103-127.6)
Female	1	2.4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	35	42.9	81.7	(56.9-113.6)					
Female	57	43.2	132.1	(100-171.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Seekonk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	20	16.3	122.4	(74.7-189.1)	Male	13	10.8	120.6	(64.2-206.3)
Female	3	5.2	nc	(nc-nc)	Female	4	7.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.1	nc	(nc-nc)	Male	2	3	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	12	9.4	127.6	(65.8-222.8)
Female	61	60.4	100.9	(77.2-129.6)	Female	5	7	71	(22.9-165.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	5	7.3	68.4	(22-159.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	18.6	64.4	(33.2-112.4)	Female	5	5.4	93.1	(30-217.3)
Female	16	16.6	96.4	(55-156.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	5.4	nc	(nc-nc)
Male	4	4.5	nc	(nc-nc)	Female	5	5	99.8	(32.2-232.9)
Female	1	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	49	63.7	76.9	(56.9-101.7)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1	nc	(nc-nc)	Male	5	3.9	127.9	(41.2-298.5)
<u>Kidney & Renal Pelvis</u>					Female	1	2	nc	(nc-nc)
Male	6	9	66.9	(24.4-145.6)	<u>Testis</u>				
Female	2	4.7	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.5	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	13	11.4	113.6	(60.4-194.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	6.3	96	(35-208.9)	Female	9	13.9	64.7	(29.5-122.9)
Female	5	4.2	120.3	(38.8-280.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	177	223.5	79.2	(68-91.8)
Male	2	5.3	nc	(nc-nc)	Female	180	200.9	89.6	(77-103.7)
Female	0	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	30.2	59.5	(35.2-94)					
Female	28	27.9	100.3	(66.7-145)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sharon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	18.1	71.6	(38.1-122.5)	Male	13	12.4	104.6	(55.6-178.9)
Female	5	6.1	82.6	(26.6-192.7)	Female	10	9.5	104.8	(50.2-192.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	6	3.4	174.8	(63.8-380.4)
Female	3	3	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.6	nc	(nc-nc)	Male	18	10.9	165.3	(97.9-261.2)
Female	87	74	117.5	(94.1-145)	Female	9	8.3	108.2	(49.4-205.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.7	nc	(nc-nc)	Male	8	8.9	90.3	(38.9-177.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	17	21.6	78.8	(45.9-126.1)	Female	8	6.5	123.3	(53.1-243)
Female	18	19.5	92.2	(54.6-145.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	6.1	163.1	(78.1-299.9)
Male	3	5.2	nc	(nc-nc)	Female	10	5.8	173.4	(83-318.9)
Female	2	1.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	76	74.4	102.2	(80.5-127.9)
Male	1	1.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.1	nc	(nc-nc)	Male	3	4.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.4	nc	(nc-nc)
Male	7	10.6	65.8	(26.3-135.5)	<u>Testis</u>				
Female	9	5.6	160.3	(73.2-304.4)	Male	6	2.2	277.3	(101.3-603.5)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.9	nc	(nc-nc)	Male	8	4.8	168.2	(72.4-331.4)
Female	1	0.8	nc	(nc-nc)	Female	26	14.2	183.5	(119.8-268.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	7.3	68.8	(22.2-160.6)	Female	15	16.9	88.8	(49.6-146.4)
Female	4	5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	243	258.1	94.2	(82.7-106.8)
Male	0	6.3	nc	(nc-nc)	Female	266	240.5	110.6	(97.7-124.7)
Female	1	1.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	20	33.8	59.1	(36.1-91.3)					
Female	34	32.1	105.8	(73.3-147.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sheffield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.7	nc	(nc-nc)	Male	3	3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	23	16.5	139.7	(88.5-209.7)	Female	1	2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	5.2	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	14	18.1	77.3	(42.2-129.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.5	nc	(nc-nc)	Female	3	3.9	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	1.5	nc	(nc-nc)	Male	5	8.7	57.6	(18.5-134.3)
Female	1	0.5	nc	(nc-nc)	Female	14	8.2	170.4	(93.1-285.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shelburne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.9	nc	(nc-nc)	Male	5	1.8	274.5	(88.5-640.6)
Female	0	1.1	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	11	10.7	103.3	(51.5-184.8)	Female	3	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	3.2	nc	(nc-nc)	Female	0	1	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	0.8	nc	(nc-nc)	Female	0	1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	14	11	127.1	(69.4-213.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	0.9	nc	(nc-nc)	Female	7	2.5	283.2	(113.5-583.6)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	6	5.3	113.2	(41.3-246.5)	Female	41	38.4	106.8	(76.6-144.9)
Female	3	5.5	nc	(nc-nc)	Female	43	37.8	113.8	(82.4-153.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sherborn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	4.8	nc	(nc-nc)	Male	8	3.2	249.5	(107.4-491.7)
Female	1	1.5	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	15	18.3	81.8	(45.7-134.9)	Female	0	2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	5.6	89.1	(28.7-207.9)	Female	1	1.6	nc	(nc-nc)
Female	2	4.7	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	1.6	nc	(nc-nc)
Male	3	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	20	19.6	102.2	(62.4-157.9)
Male	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.6	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Testis</u>				
Female	2	1.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	5	3.4	147.4	(47.5-344)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	1.9	267.2	(86.1-623.6)	Female	5	4.2	118	(38-275.3)
Female	1	1.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	64	67.3	95.1	(73.2-121.4)
Male	1	1.7	nc	(nc-nc)	Female	53	58.7	90.4	(67.7-118.2)
Female	0	0.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	3	9	nc	(nc-nc)					
Female	8	7.9	101.8	(43.8-200.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shirley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	6.4	124.6	(53.6-245.5)	Male	5	4.9	101.2	(32.6-236.3)
Female	6	2	302.5	(110.5-658.4)	Female	1	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
Female	20	23.9	83.6	(51.1-129.2)	Female	0	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	3.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	8	149.2	(77-260.7)	Female	1	2.1	nc	(nc-nc)
Female	10	6.3	157.8	(75.5-290.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.2	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	4	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	24	26.5	90.6	(58-134.8)
Male	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.8	nc	(nc-nc)
Male	8	4.2	191.3	(82.4-377.1)	<u>Testis</u>				
Female	0	1.8	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	4.8	104	(33.5-242.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.8	nc	(nc-nc)	Female	9	5.4	165.4	(75.5-314.1)
Female	1	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	110	96.6	113.8	(93.5-137.2)
Male	6	2.4	253.1	(92.4-551)	Female	81	78.6	103.1	(81.9-128.1)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	12	191.4	(121.3-287.2)					
Female	13	10.6	123	(65.4-210.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shrewsbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	35.5	104.3	(73.4-143.8)	Male	15	23.6	63.6	(35.6-104.9)
Female	9	12.9	69.6	(31.7-132.1)	Female	22	19.1	115.3	(72.2-174.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	7.2	138.7	(66.4-255)	Male	7	6.5	108.4	(43.4-223.4)
Female	3	5.9	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.1	nc	(nc-nc)	Male	34	20.8	163.1	(112.9-227.9)
Female	147	140.2	104.9	(88.6-123.2)	Female	13	17.1	76	(40.4-130)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.3	nc	(nc-nc)	Male	12	15.7	76.4	(39.5-133.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	31	40.9	75.8	(51.5-107.6)	Female	13	12.6	103.1	(54.8-176.3)
Female	38	41.5	91.6	(64.8-125.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	11.7	119.7	(65.4-200.8)
Male	14	9.5	146.7	(80.1-246.1)	Female	8	12.5	63.9	(27.5-125.9)
Female	1	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	128	131.7	97.2	(81.1-115.6)
Male	1	3	nc	(nc-nc)	<u>Stomach</u>				
Female	5	2.4	206.4	(66.5-481.7)	Male	5	8.5	58.8	(19-137.2)
<u>Kidney & Renal Pelvis</u>					Female	3	5.1	nc	(nc-nc)
Male	30	19.5	154.2	(104-220.2)	<u>Testis</u>				
Female	9	11.1	81.1	(37-154)	Male	8	5	158.9	(68.4-313.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	5.2	nc	(nc-nc)	Male	13	8.9	146.8	(78.1-251.1)
Female	1	1.6	nc	(nc-nc)	Female	13	27.4	47.4	(25.2-81.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	14.1	85.2	(44-148.8)	Female	30	31.3	95.8	(64.6-136.7)
Female	10	10.5	95.5	(45.7-175.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	479	480.9	99.6	(90.9-108.9)
Male	8	11.2	71.2	(30.6-140.3)	Female	414	479.2	86.4	(78.3-95.1)
Female	0	3.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	57	64.4	88.6	(67.1-114.7)					
Female	54	66.2	81.6	(61.3-106.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Shutesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1	nc	(nc-nc)
Female	4	7.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	0.5	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	7.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.7	nc	(nc-nc)	Female	3	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	16	24	66.7	(38.1-108.4)
Male	0	0.6	nc	(nc-nc)	Female	14	22.1	63.4	(34.6-106.4)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	2	3	nc	(nc-nc)					
Female	1	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	27.1	88.5	(56.7-131.8)	Male	13	16.5	78.6	(41.8-134.4)
Female	14	10.7	130.9	(71.5-219.7)	Female	9	13.1	68.6	(31.3-130.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.5	133.6	(48.8-290.8)	Male	4	4.7	nc	(nc-nc)
Female	4	4	nc	(nc-nc)	Female	6	4.2	142.6	(52.1-310.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	14	14.5	96.2	(52.6-161.5)
Female	86	98.9	87	(69.6-107.4)	Female	11	13.2	83.5	(41.6-149.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	3.2	nc	(nc-nc)	Male	5	10.5	47.5	(15.3-110.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	29.4	91.9	(60.6-133.7)	Female	10	9.2	108.5	(52-199.6)
Female	26	33.3	78.2	(51-114.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	8.7	125.7	(62.7-225)
Male	5	7	71.8	(23.1-167.4)	Female	8	10.4	76.7	(33-151.1)
Female	1	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	99	95.2	103.9	(84.5-126.5)
Male	4	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.4	nc	(nc-nc)	Male	11	6.2	176.7	(88.1-316.1)
<u>Kidney & Renal Pelvis</u>					Female	8	4.1	193	(83.1-380.2)
Male	11	13.2	83.3	(41.5-149.1)	<u>Testis</u>				
Female	9	8.3	108.8	(49.6-206.5)	Male	6	2.5	244.5	(89.3-532.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	3.8	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	18	15.9	113.5	(67.3-179.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	9.8	132.1	(70.3-226)	Female	21	22.7	92.4	(57.2-141.2)
Female	11	7.8	141.9	(70.7-253.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	341	344.9	98.9	(88.6-109.9)
Male	6	7.8	76.9	(28.1-167.4)	Female	321	354.9	90.4	(80.8-100.9)
Female	2	3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	50	48.7	102.6	(76.1-135.3)					
Female	40	53.3	75.1	(53.6-102.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Somerville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	55	70.9	(50.4-96.9)	Male	27	39.4	68.5	(45.1-99.6)
Female	24	22.1	108.5	(69.5-161.5)	Female	21	37.3	56.3	(34.9-86.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	13	53.9	(21.6-111.1)	Male	8	10	79.9	(34.4-157.5)
Female	11	11.2	98.6	(49.1-176.4)	Female	13	8.9	146.8	(78.1-251.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.7	nc	(nc-nc)	Male	35	34.8	100.5	(70-139.8)
Female	193	237.5	81.2	(70.2-93.6)	Female	19	30.1	63	(37.9-98.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	10.4	57.7	(21.1-125.6)	Male	28	24.9	112.4	(74.7-162.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	58	64	90.6	(68.8-117.1)	Female	17	22.2	76.7	(44.6-122.8)
Female	58	70.8	81.9	(62.2-105.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	12	14.8	81.2	(41.9-141.8)	Male	25	18.2	137.6	(89-203.1)
Female	6	4.5	134	(48.9-291.6)	Female	19	21.4	88.6	(53.3-138.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	17	7.9	214.3	(124.7-343.1)	Male	156	203.2	76.8	(65.2-89.8)
Female	1	6.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	30	31.2	96.2	(64.9-137.4)	Male	19	13.4	142.2	(85.6-222)
Female	21	19.2	109.5	(67.8-167.4)	Female	15	8.7	172.7	(96.6-284.9)
<u>Larynx</u>					<u>Testis</u>				
Male	10	8.1	123.3	(59-226.7)	Male	4	15.9	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	19	23.4	81.1	(48.8-126.6)	Male	17	16.7	101.7	(59.2-162.8)
Female	16	18.9	84.7	(48.4-137.6)	Female	60	58.1	103.2	(78.8-132.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	24	17.5	137.4	(88-204.5)	Female	44	53.4	82.5	(59.9-110.7)
Female	11	6.5	169.2	(84.3-302.8)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	117	99.6	117.5	(97.2-140.8)	Male	702	772.7	90.9	(84.3-97.8)
Female	111	113.4	97.9	(80.5-117.9)	Female	736	841.9	87.4	(81.2-94)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

South Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	21.9	100.5	(63-152.2)	Male	20	13.3	149.9	(91.5-231.6)
Female	9	8.5	106.4	(48.5-201.9)	Female	9	11.3	79.5	(36.3-151)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	0	3.5	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	12	11.8	102	(52.6-178.2)
Female	102	80.8	126.2	(102.9-153.2)	Female	7	10.7	65.4	(26.2-134.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.7	184.8	(59.6-431.4)	Male	5	8.5	58.7	(18.9-137.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	23.8	121.8	(81.6-175)	Female	5	7.6	65.5	(21.1-153)
Female	24	26.5	90.5	(58-134.6)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	3	5.6	nc	(nc-nc)	Male	80	76.4	104.8	(83.1-130.4)
Female	3	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	2	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	10.6	103.7	(51.7-185.6)	Female	22	18.6	118.3	(74.1-179.2)
Female	7	6.7	103.9	(41.6-214.1)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	7	3	230.9	(92.5-475.7)	Male	9	8	112.7	(51.4-214)
Female	0	1	nc	(nc-nc)	Female	5	6.5	77.4	(24.9-180.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	6.3	nc	(nc-nc)	Male	42	39.1	107.5	(77.5-145.3)
Female	0	2.4	nc	(nc-nc)	Female	35	42.6	82.2	(57.2-114.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.1	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	3	1	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	24	25.4	94.6	(60.6-140.8)	Female	2	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	7.3	95.7	(38.4-197.3)	Female	4	2.2	nc	(nc-nc)
Female	7	6.6	105.8	(42.4-218)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	2.1	nc	(nc-nc)
Male	0	1.8	nc	(nc-nc)	Female	4	2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	29	26.3	110.1	(73.7-158.2)
Male	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.8	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.9	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	2.4	nc	(nc-nc)	Female	8	5.9	134.7	(58-265.5)
Female	0	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	78	89	87.6	(69.3-109.4)
Male	2	2.2	nc	(nc-nc)	Female	79	82.6	95.7	(75.7-119.3)
Female	0	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	11.5	52.4	(19.1-114)					
Female	11	11.1	99.5	(49.6-178)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	8.4	155.4	(82.7-265.8)	Male	12	6.1	197.9	(102.1-345.7)
Female	2	2.7	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2	nc	(nc-nc)	Male	6	1.6	367.3	(134.1-799.5)
Female	1	1.5	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
Female	50	36.1	138.5	(102.8-182.5)	Female	4	3.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	7	4.4	160.1	(64.1-329.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	10.3	77.9	(33.5-153.5)	Female	2	3.1	nc	(nc-nc)
Female	13	8.9	145.6	(77.5-249.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	2.5	nc	(nc-nc)	Male	44	35.7	123.3	(89.6-165.5)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.8	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.3	94.4	(30.4-220.4)	Female	11	8.1	135.9	(67.8-243.2)
Female	1	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	1.4	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	4	3.1	nc	(nc-nc)	Male	13	15.8	82.1	(43.6-140.3)
Female	0	0.9	nc	(nc-nc)	Female	20	14.9	134.5	(82.1-207.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Southwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.3	97.3	(46.6-178.9)	Male	3	6.9	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	Female	4	5.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
Female	36	39.9	90.2	(63.2-124.9)	Female	8	4.8	167.6	(72.2-330.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	12	49.9	(18.2-108.5)	Female	3	3.6	nc	(nc-nc)
Female	21	11.6	181.7	(112.5-277.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	2.8	nc	(nc-nc)	Male	42	39.6	106	(76.4-143.3)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.9	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.8	86.6	(27.9-202)	Female	6	9	66.6	(24.3-144.9)
Female	1	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	1.6	nc	(nc-nc)	Male	1	4.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	5	2.9	173.8	(56-405.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	3	3.4	nc	(nc-nc)	Male	17	18.8	90.5	(52.7-144.9)
Female	2	1.1	nc	(nc-nc)	Female	12	18.7	64.2	(33.1-112.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Spencer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	13.1	160.9	(99.6-246)	Male	4	8.7	nc	(nc-nc)
Female	9	4.3	209.6	(95.6-397.9)	Female	2	6.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.6	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	3	2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.7	78.4	(28.6-170.7)
Female	45	48.8	92.2	(67.3-123.4)	Female	6	5.8	103.9	(37.9-226.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	4	6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	14	15.1	93	(50.8-156.1)	Female	2	4.4	nc	(nc-nc)
Female	16	13.5	118.1	(67.5-191.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	4.3	115.1	(37.1-268.6)
Male	3	3.6	nc	(nc-nc)	Female	1	4.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	51.5	50.5	(33-74)
Male	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.9	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.6	nc	(nc-nc)
Male	11	7.3	151	(75.3-270.2)	<u>Testis</u>				
Female	8	3.8	208.9	(90-411.7)	Male	2	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	2	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	6	9.5	63.3	(23.1-137.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	5.1	234.2	(120.9-409.1)	Female	12	11.3	106.1	(54.8-185.4)
Female	4	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	155	181	85.7	(72.7-100.3)
Male	5	4.3	116.2	(37.4-271.1)	Female	157	163.9	95.8	(81.4-112)
Female	2	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	26	24.2	107.6	(70.3-157.7)					
Female	16	22.8	70.3	(40.1-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	89	131.2	67.8	(54.5-83.4)	Male	34	86.9	39.1	(27.1-54.7)
Female	42	51.7	81.3	(58.6-109.9)	Female	39	78.6	49.6	(35.3-67.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	23	28.1	81.9	(51.9-122.8)	Male	23	23.6	97.6	(61.8-146.4)
Female	23	25.3	90.9	(57.6-136.3)	Female	17	20.8	81.6	(47.5-130.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	7	4.1	170.2	(68.2-350.7)	Male	67	77.6	86.3	(66.9-109.6)
Female	509	555.9	91.6	(83.8-99.9)	Female	56	69	81.2	(61.3-105.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	32	21.2	150.9	(103.2-213.1)	Male	60	56.6	106	(80.9-136.5)
Female	18	27.4	65.8	(38.9-103.9)	Female	18	27.4	65.8	(38.9-103.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	152	149	102	(86.4-119.6)	Female	40	50.9	78.6	(56.2-107.1)
Female	148	164.1	90.2	(76.3-106)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	46	43	106.9	(78.3-142.6)
Male	39	34.9	111.7	(79.4-152.8)	Female	39	49.9	78.2	(55.6-106.9)
Female	13	10.5	124	(65.9-212)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	481	480.4	100.1	(91.4-109.5)
Male	16	13.1	122	(69.7-198.1)	<u>Stomach</u>				
Female	14	11.7	119.6	(65.3-200.7)	Male	49	31.2	157.2	(116.3-207.8)
<u>Kidney & Renal Pelvis</u>					Female	28	20.1	139.3	(92.5-201.3)
Male	79	70.5	112.1	(88.8-139.7)	<u>Testis</u>				
Female	43	44.7	96.2	(69.6-129.6)	Male	15	22.3	67.1	(37.5-110.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	21	19.1	110	(68.1-168.2)	Male	18	32.7	55.1	(32.6-87)
Female	7	6.5	107.7	(43.1-221.9)	Female	75	114	65.8	(51.7-82.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	44	54.1	81.4	(59.1-109.3)	Female	118	126.4	93.4	(77.3-111.8)
Female	40	43.4	92.1	(65.8-125.4)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1701	1774.8	95.8	(91.3-100.5)
Male	59	40.8	144.6	(110.1-186.6)	Female	1710	1926.5	88.8	(84.6-93.1)
Female	12	15.3	78.2	(40.4-136.7)					
<u>Lung and Bronchus</u>									
Male	259	237.1	109.2	(96.3-123.4)					
Female	265	266.8	99.3	(87.7-112)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sterling

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.9	76	(27.8-165.4)	Male	5	5.5	90.5	(29.2-211.2)
Female	4	2.6	nc	(nc-nc)	Female	6	4.2	142.6	(52.1-310.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	4.8	124.4	(45.4-270.7)
Female	33	32	103.3	(71.1-145)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	9.5	74	(29.6-152.4)	Female	6	2.8	213	(77.8-463.7)
Female	10	8.5	118.1	(56.6-217.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.7	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	33	121.3	(86.6-165.1)
Male	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	4	2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	<u>Testis</u>				
Female	4	2.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.3	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	4	6.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.2	nc	(nc-nc)	Female	9	7.3	123.4	(56.3-234.3)
Female	1	2.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	108	114	94.7	(77.7-114.3)
Male	1	2.8	nc	(nc-nc)	Female	103	103.9	99.2	(80.9-120.3)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	10	14.8	67.4	(32.3-124)					
Female	11	13.5	81.3	(40.5-145.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	3.9	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	4	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	8	13.1	61.1	(26.3-120.4)	Female	4	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	4.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	14.3	76.9	(38.4-137.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	1	1.9	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	1	1.4	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.1	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	2	7.2	nc	(nc-nc)	Male	40	50.1	79.9	(57-108.7)
Female	5	7	71.2	(22.9-166.2)	Female	42	45.9	91.5	(65.9-123.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoneham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	29.2	75.3	(47.2-114.1)	Male	16	18.1	88.4	(50.5-143.6)
Female	13	11.3	115.3	(61.3-197.2)	Female	18	14.5	124	(73.4-195.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5	119	(43.4-258.9)	Male	6	5.1	117.1	(42.8-254.9)
Female	4	4.5	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.9	nc	(nc-nc)	Male	23	15.9	144.2	(91.4-216.4)
Female	132	108.7	121.5	(101.6-144.1)	Female	10	14.1	70.9	(33.9-130.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	3.6	219.5	(94.5-432.5)	Male	13	11.6	111.9	(59.5-191.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	32.1	102.8	(70.7-144.3)	Female	9	10	89.8	(41-170.5)
Female	37	35.3	104.9	(73.9-144.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	9.5	52.8	(17-123.3)
Male	6	7.6	79.5	(29-173)	Female	6	11	54.7	(20-119)
Female	3	2.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	85	103.1	82.5	(65.9-102)
Male	3	1.9	nc	(nc-nc)	<u>Stomach</u>				
Female	4	1.6	nc	(nc-nc)	Male	11	6.8	162.6	(81.1-291)
<u>Kidney & Renal Pelvis</u>					Female	4	4.4	nc	(nc-nc)
Male	17	14.5	117.2	(68.2-187.6)	<u>Testis</u>				
Female	9	9	100.4	(45.8-190.5)	Male	5	3	168.4	(54.3-393)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	4.1	171	(68.5-352.3)	Male	10	6.1	164.8	(78.9-303)
Female	2	1.3	nc	(nc-nc)	Female	24	18.5	130	(83.2-193.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	10.8	147.9	(84.5-240.3)	Female	32	24.8	129	(88.3-182.2)
Female	13	8.4	154.9	(82.4-264.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	393	375.4	104.7	(94.6-115.6)
Male	8	8.6	93.3	(40.2-183.9)	Female	421	384.8	109.4	(99.2-120.4)
Female	4	3.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	53	52.4	101.1	(75.8-132.3)					
Female	49	56.8	86.3	(63.9-114.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stoughton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	31.3	102.3	(70-144.4)	Male	20	20.4	98.3	(60-151.8)
Female	13	12	108	(57.4-184.6)	Female	19	16.8	113.3	(68.2-177)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.9	117.8	(47.2-242.8)	Male	3	5.7	nc	(nc-nc)
Female	6	5.1	116.6	(42.6-253.9)	Female	6	4.9	123.5	(45.1-268.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1	nc	(nc-nc)	Male	20	17.9	112	(68.4-173)
Female	149	126.1	118.2	(100-138.7)	Female	20	15.6	128.2	(78.3-198.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.4	113.7	(36.7-265.4)	Male	17	13.6	125	(72.8-200.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	41	35.4	115.7	(83.1-157)	Female	17	11.5	148.3	(86.3-237.5)
Female	35	37.7	92.8	(64.6-129)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	16	10.3	155.1	(88.6-251.9)
Male	12	8.5	141.4	(73-247.1)	Female	13	11.6	111.9	(59.5-191.4)
Female	7	2.5	285	(114.2-587.1)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	112	118.7	94.3	(77.7-113.5)
Male	6	2.4	249.9	(91.3-544)	<u>Stomach</u>				
Female	2	2	nc	(nc-nc)	Male	7	7.4	94.2	(37.7-194.1)
<u>Kidney & Renal Pelvis</u>					Female	10	4.6	216.5	(103.7-398.2)
Male	19	16.8	113.4	(68.2-177)	<u>Testis</u>				
Female	14	10.2	137.8	(75.3-231.2)	Male	2	3.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	4.7	129	(47.1-280.7)	Male	9	7.3	123.1	(56.2-233.7)
Female	1	1.5	nc	(nc-nc)	Female	37	22.7	163.1	(114.8-224.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	12	99.9	(51.6-174.5)	Female	25	29.1	85.8	(55.5-126.6)
Female	9	9.2	97.4	(44.5-184.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	449	421.8	106.4	(96.8-116.8)
Male	5	9.9	50.7	(16.3-118.3)	Female	504	434	116.1	(106.2-126.7)
Female	3	3.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	68	57.3	118.7	(92.2-150.5)					
Female	72	62.5	115.2	(90.2-145.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Stow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	6.3	127.6	(54.9-251.4)	Male	4	4.5	nc	(nc-nc)
Female	3	2	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	29	26.6	109	(73-156.6)	Female	5	2.9	173	(55.8-403.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	7.6	nc	(nc-nc)	Female	6	2.3	260.4	(95.1-566.8)
Female	8	6.6	121.5	(52.3-239.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.2	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	27.2	147	(105-200.2)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<u>Testis</u>				
Female	3	2	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	2.6	nc	(nc-nc)	Female	10	6.1	163	(78-299.7)
Female	1	1.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	84	92.6	90.7	(72.4-112.3)
Male	0	2.3	nc	(nc-nc)	Female	100	84.8	117.9	(95.9-143.4)
Female	2	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	11.9	nc	(nc-nc)					
Female	13	11.1	116.8	(62.2-199.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sturbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	10.4	86.4	(39.4-164)	Male	7	6.9	101.6	(40.7-209.3)
Female	6	3.4	174	(63.5-378.7)	Female	7	5.1	136	(54.5-280.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	5	6	82.9	(26.7-193.5)
Female	40	38.9	102.9	(73.5-140.2)	Female	2	4.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	2	4.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	11.9	92.4	(46.1-165.4)	Female	2	3.5	nc	(nc-nc)
Female	7	10.9	64.5	(25.8-132.8)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.5	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	43	40.7	105.8	(76.5-142.5)
Male	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.3	nc	(nc-nc)
Male	7	5.7	121.8	(48.8-251)	<u>Testis</u>				
Female	6	3.1	196.2	(71.6-427.1)	Male	1	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.6	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	4	7.4	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.1	nc	(nc-nc)	Female	22	9	245.7	(154-372.1)
Female	3	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	129	142.9	90.3	(75.3-107.2)
Male	1	3.4	nc	(nc-nc)	Female	133	130.5	101.9	(85.3-120.8)
Female	1	1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	19.3	93.4	(55.4-147.7)					
Female	16	18.3	87.6	(50.1-142.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sudbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	16.9	100.5	(58.5-160.9)	Male	17	11.8	144.3	(84-231.1)
Female	4	5.6	nc	(nc-nc)	Female	13	9	144.7	(77-247.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.7	134.6	(43.4-314.2)	Male	3	3.2	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	12	10.3	116.2	(60-203.1)
Female	105	70.1	149.8	(122.5-181.4)	Female	12	7.8	154.3	(79.6-269.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	4	8.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	25	20.4	122.7	(79.4-181.1)	Female	4	6.1	nc	(nc-nc)
Female	11	18.2	60.3	(30.1-108)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	5.7	104.4	(38.1-227.3)
Male	2	4.9	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	92	70.4	130.7	(105.4-160.3)
Male	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	1.1	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	2.2	nc	(nc-nc)
Male	8	10.2	78.5	(33.8-154.6)	<u>Testis</u>				
Female	5	5.3	95	(30.6-221.6)	Male	2	2.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.7	nc	(nc-nc)	Male	5	4.6	108.7	(35-253.7)
Female	1	0.8	nc	(nc-nc)	Female	16	13.5	118.1	(67.5-191.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	6.9	144.6	(69.2-266)	Female	9	15.8	56.8	(25.9-107.9)
Female	9	4.8	189	(86.2-358.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	239	244	98	(85.9-111.2)
Male	3	6	nc	(nc-nc)	Female	257	226	113.7	(100.3-128.5)
Female	3	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	31.8	37.7	(19.5-65.9)					
Female	30	29.7	101.2	(68.2-144.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sunderland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.7	nc	(nc-nc)	Male	1	2	nc	(nc-nc)
Female	0	1	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	11	11.7	94.1	(46.9-168.4)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	3.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	0	3.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	12	10.6	113	(58.3-197.4)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.6	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.9	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	5.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Sutton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.2	122	(58.4-224.4)	Male	8	5.9	134.5	(57.9-265.1)
Female	5	2.5	200.9	(64.7-468.9)	Female	1	4.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.9	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	11	5.2	212.4	(105.9-380.1)
Female	32	33.7	95	(65-134.2)	Female	4	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	10.1	69.3	(27.8-142.7)	Female	0	2.9	nc	(nc-nc)
Female	8	8.1	98.3	(42.3-193.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	1	2.5	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	28	36	77.7	(51.6-112.3)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	7	5.2	134.9	(54.1-278)	Male	2	2.1	nc	(nc-nc)
Female	5	2.5	200.4	(64.6-467.7)	Female	0	1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	3.4	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	7	7.1	98.6	(39.5-203.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	3.1	nc	(nc-nc)	Female	12	7.7	155.9	(80.5-272.3)
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	16	15.6	102.7	(58.7-166.8)	Male	117	122.7	95.3	(78.8-114.2)
Female	14	13.7	102.4	(55.9-171.8)	Female	103	106.9	96.4	(78.6-116.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swampscott

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	19.2	114.5	(71.7-173.4)	Male	12	11.7	102.2	(52.7-178.5)
Female	16	7.3	218.2	(124.6-354.3)	Female	11	9.5	116.2	(57.9-208)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.3	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	18	10.5	172.2	(102-272.2)
Female	86	71.3	120.7	(96.5-149)	Female	15	9.2	163.5	(91.4-269.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	5	7.6	65.5	(21.1-153)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	21.3	107.9	(68.4-162)	Female	5	6.6	76.2	(24.5-177.7)
Female	26	23.4	111.3	(72.7-163.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	6.2	96.7	(35.3-210.4)
Male	2	4.9	nc	(nc-nc)	Female	4	7.2	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	66.4	88.8	(67.6-114.6)
Male	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1	nc	(nc-nc)	Male	2	4.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	2.9	nc	(nc-nc)
Male	10	9.4	106.4	(50.9-195.6)	<u>Testis</u>				
Female	6	5.8	103.8	(37.9-225.8)	Male	3	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	2.6	nc	(nc-nc)	Male	12	3.9	308.8	(159.4-539.4)
Female	1	0.8	nc	(nc-nc)	Female	14	12	116.3	(63.5-195.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	7.2	nc	(nc-nc)	Female	25	16.1	155.2	(100.4-229.1)
Female	9	5.5	162.9	(74.3-309.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	236	244.4	96.5	(84.6-109.7)
Male	3	5.6	nc	(nc-nc)	Female	285	250.6	113.7	(100.9-127.7)
Female	0	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	33.8	85.8	(57.4-123.2)					
Female	37	35.8	103.4	(72.8-142.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Swansea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	20.4	103	(63.7-157.5)	Male	9	13.2	68.4	(31.2-129.8)
Female	15	7.3	206.2	(115.3-340.1)	Female	4	10.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	0	3.7	nc	(nc-nc)
Female	5	3.1	163.9	(52.8-382.4)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	14	11.5	121.3	(66.2-203.5)
Female	73	76.2	95.8	(75.1-120.5)	Female	5	9.4	53.2	(17.1-124)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.6	189.6	(61.1-442.5)	Male	9	8.8	102	(46.5-193.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	18	23	78.2	(46.3-123.6)	Female	9	6.9	130	(59.3-246.9)
Female	18	22.9	78.8	(46.7-124.5)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	8	5.5	144.9	(62.4-285.5)	Male	4	6.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	7	7	99.7	(39.9-205.3)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	3	1.5	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	15	10.8	138.8	(77.6-228.9)	Male	2	2.3	nc	(nc-nc)
Female	2	6.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	3	264.8	(114-521.8)	Female	14	17.6	79.6	(43.5-133.5)
Female	2	0.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Female</u>				
Male	4	7.7	nc	(nc-nc)	Male	282	273.5	103.1	(91.4-115.9)
Female	5	5.5	90.6	(29.2-211.4)	Female	235	261.7	89.8	(78.7-102.1)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	4	6.4	nc	(nc-nc)					
Female	2	2.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	38	37.2	102.3	(72.4-140.4)					
Female	28	37.6	74.6	(49.5-107.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Taunton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	55	55	100	(75.3-130.1)	Male	25	36.8	67.9	(43.9-100.2)
Female	21	21.3	98.6	(61-150.7)	Female	23	31.4	73.2	(46.4-109.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	11.3	97.2	(48.5-173.9)	Male	10	10	99.8	(47.8-183.6)
Female	7	9.8	71.8	(28.8-147.9)	Female	13	8.6	151.7	(80.7-259.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	1.7	287	(92.5-669.7)	Male	36	32.5	110.9	(77.7-153.6)
Female	237	226.8	104.5	(91.6-118.7)	Female	37	28.1	131.9	(92.8-181.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.5	94	(40.5-185.2)	Male	24	24.5	98.1	(62.9-146)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	76	63.2	120.2	(94.7-150.5)	Female	18	20.7	87.2	(51.6-137.8)
Female	94	67.9	138.4	(111.9-169.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	31	18.2	170.4	(115.7-241.8)
Male	17	14.9	114	(66.3-182.5)	Female	25	20.6	121.2	(78.4-178.9)
Female	3	4.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	197	207.3	95	(82.2-109.3)
Male	8	5	159.7	(68.8-314.6)	<u>Stomach</u>				
Female	7	4.2	166.6	(66.8-343.3)	Male	19	13.2	144	(86.7-224.9)
<u>Kidney & Renal Pelvis</u>					Female	7	8.3	84	(33.7-173.1)
Male	37	30.3	122.3	(86.1-168.5)	<u>Testis</u>				
Female	28	18.1	154.3	(102.5-223)	Male	10	8.6	116.9	(56-215)
<u>Larynx</u>					<u>Thyroid</u>				
Male	12	8.2	146.4	(75.6-255.8)	Male	15	13.9	107.5	(60.1-177.4)
Female	3	2.6	nc	(nc-nc)	Female	64	44.8	142.9	(110-182.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	19	22	86.5	(52.1-135.1)	Female	41	51.3	79.9	(57.3-108.3)
Female	10	17.2	58	(27.8-106.7)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	821	751.7	109.2	(101.9-117)
Male	16	17.5	91.3	(52.2-148.3)	Female	851	783.2	108.7	(101.5-116.2)
Female	4	6.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	128	100.4	127.5	(106.4-151.6)					
Female	127	108.9	116.6	(97.2-138.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Templeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.5	117.2	(56.1-215.5)	Male	6	5.8	103.2	(37.7-224.7)
Female	3	2.8	nc	(nc-nc)	Female	0	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.7	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.1	98.6	(31.8-230)
Female	35	30.9	113.4	(79-157.7)	Female	3	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	2	4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	8	10	80.4	(34.6-158.4)	Female	6	2.8	215.9	(78.8-470)
Female	14	8.9	157	(85.8-263.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	3	2.4	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.7	nc	(nc-nc)	Female	35	34.4	101.8	(70.9-141.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	6	4.9	122.3	(44.7-266.2)	Female	1	1.1	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	1	1.3	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	3	3.4	nc	(nc-nc)	Female	3	5.9	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	3	2.9	nc	(nc-nc)	Female	9	7	128.3	(58.6-243.6)
Female	0	0.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	16	15.9	100.5	(57.4-163.2)	Female	116	120	96.7	(79.9-115.9)
Female	26	14.5	179	(116.9-262.3)	Female	117	104.7	111.8	(92.4-133.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tewksbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	30.8	129.9	(92.8-176.9)	Male	22	20.9	105.4	(66-159.6)
Female	12	10.8	111	(57.3-193.9)	Female	9	16.5	54.6	(24.9-103.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.3	79.6	(25.6-185.7)	Male	8	5.7	139.8	(60.2-275.4)
Female	3	5.1	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1	nc	(nc-nc)	Male	12	18.2	65.9	(34-115.1)
Female	116	124.8	92.9	(76.8-111.5)	Female	14	14.6	95.9	(52.4-160.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	4.6	174.5	(75.1-343.8)	Male	13	14.4	90.6	(48.2-154.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	35.8	100.6	(70.4-139.2)	Female	17	11.1	152.8	(89-244.7)
Female	31	34.1	90.8	(61.7-128.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	9	8.7	103.8	(47.4-197.1)	Male	128	123.3	103.8	(86.6-123.4)
Female	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	2.6	nc	(nc-nc)	Male	7	4.2	167.7	(67.2-345.5)
Female	4	2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	26	17.5	148.2	(96.8-217.2)	Female	33	28.9	114.1	(78.5-160.2)
Female	6	9.8	61.5	(22.5-133.9)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	7	4.8	146.2	(58.6-301.2)	Male	21	12.2	172.5	(106.7-263.7)
Female	0	1.5	nc	(nc-nc)	Female	19	8.7	218.8	(131.7-341.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	6	10.3	58.5	(21.4-127.3)	Male	56	57.3	97.8	(73.8-127)
Female	1	3.3	nc	(nc-nc)	Female	86	57.7	148.9	(119.1-183.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.9	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	0	2	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	6	2.7	219.1	(80-476.9)
Female	27	20	135.3	(89.2-196.9)	Female	2	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	5.5	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
Female	6	6.3	95.4	(34.8-207.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	1.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	1	2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	21	17.9	117.4	(72.6-179.4)
Male	2	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	0.8	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Testis</u>				
Female	1	1.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	5	3.4	146.9	(47.3-342.8)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	1.8	nc	(nc-nc)	Female	6	4.6	129.4	(47.3-281.7)
Female	0	1.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	73	64.4	113.3	(88.8-142.5)
Male	2	1.5	nc	(nc-nc)	Female	74	70	105.7	(83-132.7)
Female	1	0.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	5	8.8	57	(18.4-132.9)					
Female	8	10.3	77.6	(33.4-152.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tolland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Topsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.1	123.1	(58.9-226.3)	Male	2	5.1	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	Female	5	3.7	133.6	(43-311.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.5	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.5	110.3	(35.6-257.5)
Female	31	29	106.8	(72.6-151.7)	Female	5	3.5	140.9	(45.4-328.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	9.2	54.6	(17.6-127.4)	Female	4	2.6	nc	(nc-nc)
Female	9	8.8	102.8	(46.9-195.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	2.7	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	44	30.5	144.2	(104.8-193.6)
Male	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	1.1	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.3	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	3	3.1	nc	(nc-nc)	Female	9	6.6	136.4	(62.2-258.9)
Female	2	2.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	114	107.9	105.6	(87.1-126.9)
Male	1	2.5	nc	(nc-nc)	Female	101	98.9	102.1	(83.1-124)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	14.8	80.9	(41.8-141.4)					
Female	16	14.1	113.5	(64.9-184.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Townsend

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.1	127.5	(58.2-242.1)	Male	5	5.4	93.1	(30-217.2)
Female	1	2.4	nc	(nc-nc)	Female	7	4.4	160.4	(64.3-330.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.7	nc	(nc-nc)
Female	34	32.9	103.4	(71.6-144.4)	Female	3	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	1	4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	9	111.6	(53.4-205.2)	Female	6	2.8	211.3	(77.1-459.8)
Female	12	8	150.6	(77.7-263.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.5	nc	(nc-nc)
Male	5	2.2	229	(73.8-534.3)	Female	4	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	17	31.9	53.4	(31.1-85.4)
Male	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.9	nc	(nc-nc)
Male	3	4.7	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.4	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	6	7	85.2	(31.1-185.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.1	nc	(nc-nc)	Female	5	7.4	67.5	(21.7-157.5)
Female	2	2.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	95	109.4	86.8	(70.2-106.1)
Male	1	2.8	nc	(nc-nc)	Female	107	104.2	102.7	(84.2-124.1)
Female	2	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	17	13.5	125.5	(73-200.9)					
Female	14	13.1	107	(58.5-179.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Truro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.6	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	19	12.1	157.5	(94.8-246)	Female	1	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	4	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	4	1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	8	13.7	58.2	(25.1-114.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	2	1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	1.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	1.1	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	6.6	nc	(nc-nc)	Female	33	47.4	69.7	(47.9-97.8)
Female	4	6	nc	(nc-nc)	Female	51	40.7	125.4	(93.4-164.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyngsborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	8.3	203.9	(118.7-326.5)	Male	6	6.3	94.5	(34.5-205.7)
Female	5	2.9	173.7	(56-405.3)	Female	3	5.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.2	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	32	39.6	80.8	(55.2-114)	Female	3	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	10.6	113.2	(58.4-197.8)	Female	3	3.4	nc	(nc-nc)
Female	8	9.6	83.3	(35.9-164.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	2.9	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	Female	3	2.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	26	36.2	71.9	(46.9-105.3)
Male	1	1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.1	nc	(nc-nc)
Male	5	5.6	89.9	(29-209.8)	<u>Testis</u>				
Female	3	2.9	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	11	8.8	125.2	(62.4-224)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.7	nc	(nc-nc)	Female	9	8.8	102.2	(46.6-194)
Female	6	2.6	227.8	(83.2-495.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	131	127.6	102.7	(85.8-121.8)
Male	9	3.2	281.6	(128.5-534.6)	Female	133	125.8	105.7	(88.5-125.2)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	15.8	145.6	(92.3-218.5)					
Female	23	15.7	146.2	(92.7-219.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Tyringham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.2	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	1.2	nc	(nc-nc)	Male	11	8.9	124.1	(61.8-222)
Female	0	1.1	nc	(nc-nc)	Female	3	7.1	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Upton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.8	102.6	(37.5-223.3)	Male	4	4.3	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.4	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.8	133.2	(42.9-310.7)
Female	32	26.5	120.6	(82.5-170.2)	Female	1	3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	7.3	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
Female	3	6.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	Female	6	2	296.7	(108.3-645.8)
Female	0	0.4	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	22	24.7	89.1	(55.8-134.9)
Male	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	0.8	nc	(nc-nc)
Male	2	3.7	nc	(nc-nc)	<u>Testis</u>				
Female	1	2	nc	(nc-nc)	Male	1	1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	7	5.5	126.9	(50.8-261.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	2.5	200.5	(64.6-467.8)	Female	11	5.9	186.6	(93-334)
Female	2	1.8	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	85	86.8	97.9	(78.2-121)
Male	3	2.1	nc	(nc-nc)	Female	101	86.2	117.2	(95.4-142.4)
Female	0	0.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	15	11	136.7	(76.5-225.5)					
Female	10	11.2	89.2	(42.7-164)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Uxbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	11.6	111.7	(59.4-191)	Male	11	8.2	134.2	(66.9-240.2)
Female	6	4.2	142	(51.8-309)	Female	3	6.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	7.2	152.8	(76.2-273.4)
Female	57	49.5	115.2	(87.3-149.3)	Female	4	5.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.9	nc	(nc-nc)	Male	11	5.7	193.9	(96.7-347)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	13.9	79.1	(39.5-141.6)	Female	1	4.4	nc	(nc-nc)
Female	12	13.6	88.4	(45.6-154.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.9	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	Female	5	4.1	123.4	(39.8-287.9)
Female	1	0.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	46.6	126.7	(96.4-163.4)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.9	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.6	nc	(nc-nc)
Male	6	6.9	86.5	(31.6-188.3)	<u>Testis</u>				
Female	5	3.8	130.4	(42-304.2)	Male	4	1.9	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.8	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	9	10.1	89.2	(40.7-169.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	4.8	124.4	(45.4-270.8)	Female	12	11.1	108.2	(55.9-189.1)
Female	6	3.5	169.6	(61.9-369.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	207	166.4	124.4	(108.1-142.6)
Male	4	4	nc	(nc-nc)	Female	172	164.8	104.4	(89.3-121.2)
Female	1	1.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	30	21.6	138.9	(93.7-198.3)					
Female	24	22.3	107.8	(69-160.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wakefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	33	28.5	115.9	(79.8-162.8)	Male	21	18.5	113.3	(70.1-173.2)
Female	6	10.9	55.3	(20.2-120.3)	Female	24	15.2	158.4	(101.5-235.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.4	110.3	(40.3-240.1)	Male	4	5.1	nc	(nc-nc)
Female	5	4.6	107.7	(34.7-251.3)	Female	4	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	13	16.3	79.7	(42.4-136.3)
Female	135	112.5	120	(100.6-142)	Female	22	14	157	(98.4-237.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4	nc	(nc-nc)	Male	11	12.2	89.9	(44.8-160.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	36	32.2	111.8	(78.3-154.8)	Female	8	10.2	78.2	(33.7-154.2)
Female	31	34.5	90	(61.1-127.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	7	9.3	75.1	(30.1-154.7)
Male	7	7.6	91.9	(36.8-189.3)	Female	12	10.5	114	(58.8-199.2)
Female	3	2.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	91	105.2	86.5	(69.7-106.2)
Male	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	1	1.8	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	4.2	nc	(nc-nc)
Male	9	15.2	59.3	(27.1-112.6)	<u>Testis</u>				
Female	9	9	99.5	(45.4-188.9)	Male	6	3.6	166.9	(61-363.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	6	4.2	143.6	(52.4-312.6)	Male	5	6.7	74.6	(24-174)
Female	2	1.3	nc	(nc-nc)	Female	25	20.7	120.8	(78.2-178.3)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	11	100.5	(50.1-179.7)	Female	18	25.5	70.7	(41.9-111.7)
Female	8	8.4	94.9	(40.8-186.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	354	380.5	93	(83.6-103.2)
Male	6	8.9	67.4	(24.6-146.8)	Female	414	389.2	106.4	(96.4-117.1)
Female	5	3.2	158.4	(51.1-369.7)					
<u>Lung and Bronchus</u>									
Male	47	51.7	90.9	(66.7-120.8)					
Female	57	55.3	103.1	(78.1-133.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Wales

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	2	1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	7	7.3	96	(38.5-197.9)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	2.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	5	1.7	287.2	(92.6-670.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	0.5	nc	(nc-nc)	Male	5	7.9	63.4	(20.4-147.9)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.1	nc	(nc-nc)	Female	5	1.7	290.9	(93.7-678.9)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	1	0.7	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	5	3	167.9	(54.1-391.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;